Carbon ion therapy for recurrent rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of radiation called carbon ion therapy for people whose rectal cancer has returned in the same area after previous radiation. This approach aims to target the recurrent tumor while protecting nearby healthy organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has come back in the same area after your first treatment.
- You had surgery to remove the original tumor and nearby lymph nodes.
- You received radiation therapy to the pelvic area before, with or without chemotherapy.
- It has been at least one year since your last radiation treatment.
- This is your first repeat radiation treatment for the recurrence.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of contact X-ray (brachytherapy) for early-stage rectal cancer. It may help avoid major surgery by treating the tumor from inside the rectum.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.
This trial tests a new type of radiation using carbon ions to treat large tumors in the chest that have come back or not responded to prior treatments. It aims to see if this therapy is safe and effective for people who have few options.
This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.